Advanced Pancreatic Adenocarcinoma With Complete Response to Chemoimmunotherapy: A Case Report and Single‐Cell Profiling
Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis, especially in unresectable disease. We report a patient with metastatic PDAC who achieved durable complete remission after PD‐1 blockade combined with gemcitabine and albumin‐bound paclitaxel and remains disease‐free 4 years after diagnosis. To explore the immune basis of this response, we performed single‐cell RNA sequencing of peripheral blood mononuclear cells from seven patients receiving the same regimen. Responders showed enrichment of terminally differentiated CD8 + T (Temra) and CD4 ISG + T helper (Th) cells compared with nonresponders. Across independent cohorts, these two programs were positively correlated, suggesting coordinated immune activation during effective therapy. Predicted ligand–target interactions were linked to cytotoxic and immune activation pathways. These findings suggest that coordinated expansion of CD4 + ISG + Th and CD8 + Temra cells are associated with durable chemoimmunotherapy responses in PDAC and support peripheral blood immune profiling as a minimally invasive monitoring strategy. Trial Registration: ClinicalTrials.gov identifier: NCT05201729
Authors
- Taojing Ran
- Duowu Zou (ORCID: https://orcid.org/0000-0002-2461-5304)
- Xinchen Lu
- Zonghao Liu (ORCID: https://orcid.org/0009-0003-1522-7320)
- ChenXiao Liu (ORCID: https://orcid.org/0009-0008-1809-5788)
- Benyan Zhang
- Lili Gao
- Chunhua Zhou
- Yao Zhang
Institutions
- Shanghai Jiao Tong University (CN)
- Ruijin Hospital (CN)
Publication Details
- Journal
- Cancer Science
- Published
- 2026-11-20
- DOI
- https://doi.org/10.1111/cas.70599
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00